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Background: Frontotemporal dementia (FTD) may present with psychiatric symptoms, usually together with
neurological ones and in cases with a family history of dementia. We describe the case of an FTD behavioural
variant with a psychiatric presentation and a normal neurological examination, due to a C9Orf72 gene mutation.
Case presentation: The patient was a 57 years-old Caucasian woman with a recent onset of bizarre behaviours
and mystic delusions. She had a negative clinical history for previous psychiatric disorders and treatments and this
was her first admission to a Psychiatry Ward. A careful assessment was performed including, beyond psychiatric
evaluation, the following: blood sampling, neurological examination (including electroencephalogram,
electroencephalogram with zygomatic electrodes, Positron Emission Tomography, Cerebrospinal Fluid Analysis),
carotid artery Doppler ultrasound, brain Magnetic Resonance Imaging – angio Magnetic Resonance Imaging.
Blood sampling for the genetic assessment of mutations associated to primary dementias was performed as well:
the genes investigated were FUS, C9Orf72, PSEN-1, PSEN-2.
Conclusions: Serological tests were negative, neurological examination was normal, instrumental examinations
showed theta waves in the posterior temporal areas bilaterally and frontotemporal cortical atrophy bilaterally. The
genetic assessment of mutations associated revealed she carried a GGGGCC hexanucleotide repeat expansion
(at least 80 repeats) in C9Orf72 intron 1. Patients carrying the C9Orf72 mutation are likely to receive a psychiatric
diagnosis (mainly mood disorder or schizophrenia) prior to correct diagnosis; this may be particularly problematic
for those patients with no neurological signs to orientate diagnosis. Understanding the manner in which such FTD
variant may present as a psychiatric syndrome, with a negative neurological examination, is essential to provide the
best treatment for patients, as soon as possible, especially when the behavioural anomalies interfere with their care.
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Frontotemporal dementia (FTD) is one of the most com-
mon young-onset dementia and its clinical presentation is
characterised by progressive behavioural change, executive
dysfunction and language difficulties [1]. The clinical spec-
trum of FTD encompasses three distinct syndromes: the
behavioural variant (bvFTD) and the language variants,
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unless otherwise stated.(PNFA). FTD often overlaps with motor neuron disease
(FTD-MND or FTD-ALS), as well as parkinsonian syn-
dromes, progressive supranuclear palsy (PSP) and cortico-
basal syndrome (CBS) [2]. A positive family history is
reported in 30-50% of patients suffering from bvFTD,
while patients with SD or PNFA have a much lower
frequency [3]. In 2006, a locus on chromosome 9p21 was
associated with a large proportion of ALS and FTD cases
[4]. Recently, two independent groups reported identifica-
tion of the FTD/ALS gene defect on chromosome 9p as be-
ing a massively expanded GGGGCC hexanucleotide repeat
in a non-coding region of the chromosome 9 open readingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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sion leads to the loss of an alternatively spliced transcript
and the accumulation of RNA fragments composed of the
repeated nucleotides as RNA foci in the nucleus and/or
cytoplasm of affected cells [7]. Such foci may be toxic: they
have been shown to sequester some RNA-binding proteins
leading to dysregulation of alternative mRNA splicing [8].
Even though further studies are required, aberrant RNA
splicing is a highly plausible mechanism in chromosome
9p-linked FTD/ALS given the accumulating evidence for
RNA misprocessing in the pathogenesis of both ALS and
FTD [9].
The phenotypic spectrum of bvFTD and its pathophysi-
ologic basis have yet to be fully defined. Psychiatric mani-
festations including delusions, hallucinations, and severe
anxiety disorders may be presenting features, as described
by Arighi and coworkers [10] in three cases with a positive
family history of dementia; only one of the three cases
described, anyway, had not neurological symptoms. Al-
though a precise neuroanatomic-phenotypic correlation
has yet to be described, some clinical features, in particu-
lar neuropsychiatric symptoms, may be due to an altered
cortico-thalamo-cerebellar network [11].
Case presentation
We describe here the case of a 57 years-old woman
who came to our attention in October, 2012 because of
bizarre behaviours and mystic delusions.
She had completed junior high school, had worked until
aged 54 and then retired to look after her grandson.
Her clinical history was negative for previous psychi-
atric diagnoses and treatment. Her medical history was
significant for a cryptogenetic epilepsy: at the time of our
examination she was under treatment with Levetiracetam
1000 mg/day. Interestingly, her mother died aged 59,
suffering from a rapidly progressive dementia (duration of
illness: 11 months); while her father died aged 67 because
of myocardial infarction. Her three siblings, aged 45, 47
and 53, were healthy, and so was her offspring, although it
cannot be excluded that they develop neurological or
psychiatric symptoms in the future.
When admitted to our Day Hospital service, she was
also taking Escitalopram as prescribed by her Neurologist
who diagnosed an “anxious-depressive syndrome due to
worries about her relatives’ health problems”.
On examination, the patient was alert, partially oriented
and well groomed, she was overly familiar, perseverative
and critical of others (her husband above all) throughout
the interview. She showed poor insight into her symp-
toms, making excuses for her behaviours. She reported
episodes of amnesia without consciousness alterations
and she complained she could not recognize familiar
faces and places, together with insomnia (early awakenings)
and coloured visions. During the interviews, a memoryimpairment emerged together with episodes of confabula-
tion and an inconstant attention.
Her husband described bizarre behaviours, such as
childish tantrums, sleeping at eating times in order to
avoid having dinner with her husband, complaining about
him beating her “because he is a nasty boy”. Moreover, the
patient’s religious interests had progressively increased
until they severely interfered with daily activities. The pa-
tient wouldn’t give explanations for her behaviours and
she would only say “it’s my husband’s fault, he always tells
me off”.
Clinical assessment
Blood sampling was performed, and the patient resulted
negative for HBV, HCV, HIV and pox.
Her neurological examination was normal except for a
facetious attitude. No disorientation, focal signs, altered
reflexes nor abnormal plantar responses were detectable.
Neither Parkinsonism nor Motor Neuron Disease (MND)
signs were observed.
Her clinical assessment also included an elecroence-
phalogram (EEG), followed by an EEG with zygomatic
electrodes which both showed theta waves in the posterior
temporal areas, bilaterally.
The patient also underwent carotid artery Doppler ultra-
sound, which revealed a regular lumen of the common,
internal and external carotid and of the vertebral artery,
bilaterally.
Her brain MRI – angio MRI showed a marked fronto-
temporal cortical atrophy, bilaterally, with a broadening
of cortical burrows and ventricula. The cerebellum cortex
also presented atrophy. The left fronto-opercolar subcor-
tical white matter showed altered signal consistent with
previous small ischemic sequelae.
Psychometric assessment
Her Minnesota Multiphasic Personality Inventory-2
(MMPI-2) was consistent with a tendency to pessimism
and difficulties as regards integration in a group. Her
relationship with the environment appeared characterized
by a tendency to neurotic exploitation, by means of hy-
pochondriac – hysteric symptoms. This means that her
relationship with other people was characterized by the
unconscious tendency to try to obtain attention and care
through her physical symptoms, instead of expressing
herself in a clear and assertive way. In stressful situations,
she might show affective lability and impulsiveness. She
complained feeling hostile and aggressive and she did not
express her feelings in an assertive way. She used a “som-
atic language” in order to express her psychological and
emotional issues, while appearing unhappy, confused and
uneasy in social relations. Patients with such results are
usually diagnosed with a schizotypic personality with a
chronic tendency to hypochondriac conversion both of
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“replace” the expression of their feelings and emotions
(especially anxiety) with physical symptoms and somatic
complaints.
At the Wechsler Adult Intelligent Scale- Revised
(WAIS-R), she scored as follows: Global IQ = 77; Verbal
IQ = 71; Performance IQ = 90. Her performance was par-
ticularly poor on Comprehension, Analogies, Arithmetic
Reasoning and Stories Rearrangement. Being her Perform-
ance IQ 19 points greater than her Verbal IQ, we further
investigated her profile, as Literature suggests when scores
differ by more than 15 points. A Performance IQ greater
than the Verbal IQ suggests a left hemisphere damage.
Our patient scored rather low at each of the subtests,
particularly we observed: low interest and difficulty re-
trieving information, scarce fluid intelligence possibly due
to brain damage, low motivation, inadequate attention
and concentration abilities, difficulties controlling feelings,
low thought flexibility, poor ideas, abstraction difficulties,
concrete thought.
The patient also underwent a neuropsychological screening
test (Milan Overall Dementia Assessment - MODA):
her score (82.4) was lower than expected according to
age (range: 85.5-89.1). Her performance was worse on
“Temporal Orientation”, “Verbal Intelligence” and “Verbal
Production”. She was later administered the Frontal
Assessment Battery (FAB) in order to globally assess
the effectiveness of her executive functions. The score she
obtained (14/18) is slightly higher than the cut-off value
(12), and indicates poor performances at the “Affinity”
and “Phonemic Fluency” trials. Finally, she underwent in-
depth neuropsychological tests in order to evaluate her
ability to search for words, by means of the “Fluency
Test”, and verbal abilities requiring judgment capacities,
by means of the “Verbal Judgment” tests. The patient
scored as “pathologic” at the items Phonemics and
Semantics (both scores = 0). She scored 21/60 at the item
“Verbal Judgment”, which is definitely lower than the
range values (M = 51, DS = 6.42), thus indicating a deficit
of reasoning abilities, conceptualization, categorization
and critical-logical abilities.
During her Day Hospital treatment at the Institute of
Psychiatry in Novara, Escitalopram was withdrawn and a
treatment with Promazine up to 60 mg/day was initiated.
Her bizarre behaviours gradually diminished, and she
obtained a restful sleep again.
As a consequence of the Neurologic examinations she
underwent, the Neurologist suggested further investi-
gation requiring hospitalization at the Neurology ward.
She then underwent CSF analysis which revealed normal
values of amyloid protein (862, range values >500 pg/ml),
tau (147, range values <450 pg/ml), fosfotau (27, range
values <61 pg/ml), and plasmatic progranulin (126, range
values >61.55 ng/ml).The brain PET performed with 18FDG was consistent
with a cortical non homogenous distribution of the
marker, related to the renown atrophy.
Given these results, upon the patient's next of kin (her
husband) written informed consent, the patient under-
went blood sampling for the genetic assessment of mu-
tations associated to primary dementias: on a first step,
the genes investigated were FUS and C9Orf72; DNA was
stored for further analyses to be performed including
PSEN-1 and PSEN-2 genes, that were not analyzed at
first due to the normal CSF profile and the very low muta-
tional frequency in primary dementias. Such assessment
revealed she carried a GGGGCC hexanucleotide repeat
expansion (at least 80 repeats) in C9Orf72 intron 1. No
mutations were found in the FUS gene; PSEN-1 and
PSEN-2 were not analyzed.
Conclusions
Our patient presented a GGGGCC hexanucleotide
repeat expansion of C9Orf72: some Authors [5] claim
that the GGGGCC repeat length in healthy individuals
ranges from 2–23 hexanucleotide units, whereas they esti-
mate the repeat length to be 700–1600 units in FTD/ALS
patients based on DNA from lymphoblast cell lines. Yet,
accurate sizing of the repeat is challenging, especially in
DNA extracted from peripheral blood and brain tissue
samples, and the same Authors state that the minimal
repeat size needed to cause FTD/ALS still has to be deter-
mined and may be significantly smaller.
C9Orf72 neuroimaging assessment is characterized by
a greater atrophy in the cerebellum compared to sporadic
FTD patients and age-matched healthy controls [12].
Thus, cerebellar atrophy and its concomitant dysfunction
might represent a biomarker for a C9Orf72 mutation.
However, patients carrying the C9Orf72 mutation do not
show classic cerebellar dysfunction symptoms, such as
ataxia, and dysarthria. Nonetheless, cerebellar patients are
often described as presenting with an intellectual function-
ing impairment, together with emotional or psychiatric
disturbances. Recent evidence suggests that cerebellar pa-
tients can show cognitive and affective deficits, in parti-
cular executive dysfunction, impaired spatial memory, and
personality changes such as disinhibited or inappropriate
behaviour, which sometimes raises to psychotic features
[13]. Such psychiatric disturbances due to cerebellar dys-
function are in accordance with the finding that C9Orf72
patients show a higher incidence of psychiatric symptoms
compared to sporadic FTD cases [14]. As recently repor-
ted, psychotic symptoms may be associated with the
C9Orf72 repeat expansion, in some cases even in the
absence of neurological signs and with no evidence of
atrophy on neuroimaging [15]. Understanding the manner
in which such FTD variant may present as a neuropsychi-
atric syndrome is essential to avoid wrong diagnoses and
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C9Orf72 repeat expansion may be suggested in patients
with late-onset psychotic symptoms, with no previous his-
tory of psychiatric disorders [15], who need to be carefully
differentiated from subjects affected by schizophrenia, that
usually presents at a younger age.
The patient we described actually came to the atten-
tion of Psychiatrists earlier than of Neurologists, being
her main symptoms represented by bizarre behaviours
and mystic delusions, while her memory impairment
and executive dysfunction only emerged during our exa-
mination. Moreover, her neurologic examination kept
normal, faced with imaging evidence of cortical and
cerebellar atrophy, similarly to the case described by
Arighi and coworkers [10]. Interestingly, the patient's
CSF biomarkers were all in normal range, as previously
reported in FTD patients carrying GRN [16] and MAPT
mutations [17]. In these patients, CSF concentration of
tau and P-181 tau protein, classically considered markers
of neurodegeneration, was reported to be either normal
or borderline, despite extensive neuronal loss observed
on brain imaging and severe symptoms. Our patient's
CSF findings are therefore in line with previous similar
C9Orf72 cases reported.
Our case report is meant to underline the importance of
a correct family history collection (our patient’s siblings
and offspring should also undergo genetic assessment)
and subsequent diagnosis. Even though treatments which
have been used in bvFDT to date are all symptomatic, and
no specific treatment for psychosis in FTD is currently
available [18], a correct diagnosis may allow an improve-
ment of the patients’ quality of life, especially when the
behavioral anomalies interfere with their care. That is the
case of antipsychotics, such as Promazine, which are par-
ticularly effective in case of psychomotor agitation, and
proved an effective and tolerable treatment in our patient.
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